Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STAG2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STAG2 Recombinant Protein / Cohesin Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View STAG2 Products |
| Gene Delivery | STAG2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View STAG2 Products |
| Benchmark Ab | Anti-STAG2 Antibody Recombinant positive control for western blot and IHC. |
View STAG2 Products |
| Validator | STAG2 siRNA Set For knockdown verification in synthetic lethality screens. |
View STAG2 Products |
| Related Target A | STAG1 Essential paralog; primary therapeutic target for STAG2-mutated cancers. |
View STAG1 Products |
| Related Target B | RAD21 Cohesin core subunit; crucial for assessing STAG1/2 complex assembly. |
View RAD21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cohesin complex reconstitution in vitro | High-purity STAG2, STAG1, and RAD21 proteins strictly verified by mass spectrometry. |
| Isogenic cell line generation (STAG2 KO/WT) | High-titer Lentivirus premade particles optimized for stable integration. |
| Lack of Controls | Clinical-grade benchmark antibodies included for target validation. |
| False Positives | Validated siRNA included for sequence-specific knockdown verification. |
Live STAG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for STAG2 is anchored in the concept of synthetic lethality. As one of the most frequently mutated genes across diverse cancers (including Ewing sarcoma, bladder cancer, and acute myeloid leukemia), STAG2 loss of function creates an absolute dependency on its paralog, STAG1.
The race for STAG2-deficient therapeutics is intensifying, with major players shifting focus from traditional cytotoxic drugs to selective STAG1 small-molecule inhibitors and degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise disruption of the cohesin complex interface and the exploitation of DNA damage response (DDR) vulnerabilities in STAG2-mutated backgrounds.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| STAG1 Inhibitors (Small Mol) | Repare Therapeutics, Vicinitas | STAG2-Mutated Solid Tumors | Selectivity assays requiring high-purity STAG1 vs. STAG2 recombinant proteins. |
| PROTAC / Degraders | Arvinas, C4 Therapeutics | Ewing Sarcoma, AML | Ubiquitination and degradation assays utilizing full-length STAG2/STAG1 proteins. |
| DDR Combinations | AstraZeneca, GSK | Urothelial Carcinoma | Isogenic cell line validation using STAG2 lentivirus and siRNA knockdown models. |